Butylphthalein sodium chloride injection has good therapeutic effect for the treatment of mild to moderate acute ischemic cerebral infarction, which can reduce the chance of disability in cerebral infarction patients to a certain extent. Butylphthalide Sodium Chloride Injection is mainly composed of butylphthalide, which can reduce the area of local cerebral infarction, reduce cerebral edema, improve cerebral energy metabolism as well as microcirculation and blood flow in the ischemic area, inhibit apoptosis of neural cells, and to a certain extent, anti-cerebral thrombosis and anti-platelet aggregation. In addition, butylphthalein sodium chloride injection may also reduce the occurrence of cerebral infarction to some extent by reducing the content of arachidonic acid, increasing the level of cerebrovascular endothelial NO and PG12, inhibiting glutamate release, reducing intracellular calcium concentration, inhibiting free radicals, improving antioxidant enzyme activity, and increasing blood flow in the ischemic area. In addition, although butylphthalein sodium chloride injection has obtained good effect in clinical application, for some users, adverse reactions such as dizziness, headache, chest tightness, diarrhea and lower platelet count can occur, but the incidence is low, and when adverse reactions occur, the drug dosage should be adjusted under the guidance of a doctor.